Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP3 | P08254 | 14/20 | 0.79 |
| ▸ | MMP13 | P45452 | 5/20 | 0.78 |
| ▸ | MMP1 | P03956 | 4/20 | 0.78 |
| ▸ | MMP8 | P22894 | 4/20 | 0.78 |
| ▸ | MMP7 | P09237 | 2/20 | 0.78 |
| ▸ | MMP12 | P39900 | 2/20 | 0.78 |
| ▸ | MEP1B | Q16820 | 2/20 | 0.71 |
| ▸ | BMP1 | P13497 | 1/20 | 0.70 |
| ▸ | MMP2 | P08253 | 3/20 | 0.69 |
| ▸ | MMP14 | P50281 | 3/20 | 0.69 |
| ▸ | ADAMTS4 | O75173 | 1/20 | 0.69 |
| ▸ | ADAMTS5 | Q9UNA0 | 1/20 | 0.69 |
| ▸ | MMP9 | P14780 | 2/20 | 0.69 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6418821 | 0.91 | MMP13 (0.76) | MMP3MMP13MMP1MMP8MMP7 | |
| SCHEMBL26776651 | 0.90 | MMP13 (0.74) | MMP3MMP13MMP1MMP8MMP7 | |
| SCHEMBL7350210 | 0.88 | MMP3 (1.00) | MMP3MMP13MMP1MMP8MMP7 | |
| SCHEMBL1566876 | 0.88 | MMP13 (1.00) | MMP3MMP13MMP1MMP8MMP7 | |
| SCHEMBL1566873 | 0.88 | MMP13 (1.00) | MMP3MMP13MMP1MMP8MMP7 | |
| SCHEMBL1566475 | 0.88 | MMP13 (1.00) | MMP3MMP13MMP1MMP8MMP7 | |
| SCHEMBL7348184 | 0.87 | MMP3 (0.82) | MMP3MMP13MMP1MMP8MMP7 | |
| SCHEMBL26776615 | 0.87 | MMP3 (0.83) | MMP3MMP13MMP1MMP8MMP7 | |
| SCHEMBL7346040 | 0.86 | MMP3 (1.00) | MMP3MMP13MMP1MMP8MMP7 | |
| SCHEMBL26781503 | 0.86 | MMP3 (0.76) | MMP3MMP13MMP1MMP8MMP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 164 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260009051-A1 | COMPOSITIONS AND METHODS FOR ARTIFICIAL PROTOSPACER ADJACENT MOTIF (PAM) GENERATION | VOR BIOPHARMA INC. (US) | 2026-01-08 | — | — | US | claimed |
| EP-4555091-A2 | COMPOSITIONS AND METHODS FOR ARTIFICIAL PROTOSPACER ADJACENT MOTIF (PAM) GENERATION | Vor Biopharma Inc. (US) | 2025-05-21 | — | — | EP | claimed |
| US-20250011425-A1 | COMPOSITIONS AND METHODS FOR IMPROVED T CELLS | UNIV TEMPLE (US) | 2025-01-09 | — | — | US | claimed |
| US-12024715-B2 | Compositions and methods for improved T cells | TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2024-07-02 | — | — | US | claimed |
| WO-2024015925-A2 | COMPOSITIONS AND METHODS FOR ARTIFICIAL PROTOSPACER ADJACENT MOTIF (PAM) GENERATION | VOR BIOPHARMA INC. (US) | 2024-01-18 | — | — | WO | claimed |
| CN-111803646-B | Solid tumor combination treatment composition | 苏州大学 | 2022-07-05 | — | — | CN | claimed |
| US-20100119489-A1 | Stimulation of Pancreatic Beta Cell Proliferation | STOFFEL MARKUS | 2010-05-13 | — | — | US | claimed |
| EP-1896605-A2 | STIMULATION OF PANCREATIC B CELL PROLIFERATION | The Rockefeller University (US) | 2008-03-12 | — | — | EP | claimed |
| WO-2006133333-A2 | STIMULATION OF PANCREATIC B CELL PROLIFERATION | THE ROCKEFELLER UNIVERSITY (US) | 2006-12-14 | — | — | WO | claimed |
| WO-2026107352-A1 | COMPOSITIONS AND METHODS FOR EFFICIENT NUCLEIC ACID ASSEMBLY AND TISSUE ENGINEERING | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2026-05-21 | — | — | WO | disclosed |
| US-20260061086-A1 | COMPOUNDS COMPRISING A FIBROBLAST ACTIVATION PROTEIN LIGAND AND USE THEREOF | 3B PHARMACEUTICALS GMBH (DE) | 2026-03-05 | — | — | US | disclosed |
| US-20260009051-A1 | COMPOSITIONS AND METHODS FOR ARTIFICIAL PROTOSPACER ADJACENT MOTIF (PAM) GENERATION | VOR BIOPHARMA INC. (US) | 2026-01-08 | — | — | US | disclosed |
| WO-2025226325-A2 | IN VITRO SYSTEMS FOR GENERATION OF SKIN EQUIVALENTS AND USES THEREOF AND METHODS FOR DIAGNOSIS AND TREATMENT OF CONNECTIVE TISSUE DISORDERS | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE (US) | 2025-10-30 | — | — | WO | disclosed |
| US-12427210-B2 | Compounds comprising a fibroblast activation protein ligand and use thereof | 3B PHARMACEUTICALS GMBH (DE) | 2025-09-30 | — | — | US | disclosed |
| US-5646167-A | ADMINISTERED AS METALLOPROTEINASE INHIBITOR, ANTITUMOR OR ANTICARCINOGENIC AGENT | CIBA-GEIGY CORPORATION (US) | 1997-07-08 | — | — | US | disclosed |
| WO-1996040101-A1 | CERTAIN ARYLSULFONAMIDO-SUBSTITUTED HYDROXAMIC ACIDS FOR THE TREATMENT OF CERTAIN TUMORS | NOVARTIS AG (CH) | 1996-12-19 | — | — | WO | disclosed |
| US-5552419-A | METALLOPROTEINASE INHIBITORS | CIBA-GEIGY CORPORATION (US) | 1996-09-03 | — | — | US | disclosed |
| US-5506242-A | METALLOELASTASE INHIBITOR; TREATS EMPHYSEMA | CIBA-GEIGY CORPORATION (US) | 1996-04-09 | — | — | US | disclosed |
| US-5455258-A | Useful as inhibitors of matrix-degrading metalloproteinase enzymes such as stromelysin and/or collegenase | CIBA-GEIGY CORPORATION (US) | 1995-10-03 | — | — | US | disclosed |
| EP-0606046-A1 | Arylsulfonamido-substituted hydroxamic acids | CIBA-GEIGY AG (CH) | 1994-07-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260061086-A1 | COMPOUNDS COMPRISING A FIBROBLAST ACTIVATION PROTEIN LIGAND AND USE THEREOF | FAP, FIBP, FGF23 | MMP3 390/4885MMP13 377/4885MMP1 182/4885 |
| US-12427210-B2 | Compounds comprising a fibroblast activation protein ligand and use thereof | FIBP, FGF2, FRS2 | MMP3 533/4885MMP13 347/4885MMP1 234/4885 |
| US-20260009051-A1 | COMPOSITIONS AND METHODS FOR ARTIFICIAL PROTOSPACER ADJACENT MOTIF (PAM) GENERATION | ZFR, DCLRE1B, ZFX | MMP3 3782/4885MMP13 3723/4885MMP1 4359/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.